Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

Authors: Peters, Solange, Trigo, José, Besse, Benjamin, Moreno, Victor, Navarro, Alejandro, Eugenia Olmedo, Maria, Paz-Ares, Luis, Grohé, Christian, Antonio Lopez-Vilariño, José, Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Nieto, Antonio, Zeaiter, Ali, Subbiah, Vivek

Source: In Lung Cancer February 2024 188

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Authors: Mateos, María Victoria, Prosper, Felipe, Martin Sánchez, Jesús, Ocio, Enrique M., Oriol, Albert, Motlló, Cristina, Michot, Jean‐Marie, Jarque, Isidro, Iglesias, Rebeca, Solé, María, Martínez, Sara, Kahatt, Carmen, Fudio, Salvador, Corral, Gema, Zeaiter, Ali, Montilla, Lola, Ribrag, Vincent

Source: Cancer medicine. 12(4):3999-4009

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100181642550.0x000001&indx=1&recIds=ETOCvdc_100181642550.0x000001

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Authors: Aix, Santiago Ponce, Ciuleanu, Tudor Eliade, Navarro, Alejandro, Cousin, Sophie, Bonanno, Laura, Smit, Egbert F, Chiappori, Alberto, Olmedo, Maria Eugenia, Horvath, Ildiko, Grohé, Christian, Farago, Anna F, López-Vilariño, José Antonio, Cullell-Young, Martin, Nieto, Antonio, Vasco, Noelia, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Carcereny, Enric, Roubec, Jaromir, Syrigos, Konstantinos, Lo, Gregory, Barneto, Isidoro, Pope, Anthony, Sánchez, Amparo, Kattan, Joseph, Zarogoulidis, Konstantinos, Waller, Cornelius F, Bischoff, Helge, Juan-Vidal, Oscar, Reinmuth, Niels, Dómine, Manuel, Paz-Ares, Luis

Source: Lancet.Respiratory medicine. 11(1):74-86

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100178078822.0x000001&indx=1&recIds=ETOCvdc_100178078822.0x000001

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

Authors: Leary, Alexandra, Oaknin, Ana, Trigo, José Manuel, Moreno, Victor, Delord, Jean-Pierre, Boni, Valentina, Braña, Irene, Fernández, Cristian, Kahatt, Carmen, Nieto, Antonio, Cullell-Young, Martin, Zeaiter, Ali, Subbiah, Vivek

Source: In European Journal of Cancer October 2023 192

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study

Authors: Longo-Muñoz, Federico, Castellano, Daniel, Alexandre, Jerome, Chawla, Sant P., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Zeaiter, Ali, Moreno, Victor, Sanz-García, Enrique, Awada, Ahmad, Santaballa, Ana, Subbiah, Vivek

Source: European journal of cancer. 172:340-348

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100170791811.0x000001&indx=1&recIds=ETOCvdc_100170791811.0x000001

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

Authors: Kristeleit, Rebecca ^{1, *}, Moreno, Victor ², Boni, Valentina ³, Guerra, Eva M ⁴, Kahatt, Carmen ⁵, Romero, Ignacio ⁶, Calvo, Emiliano ³, Basté, Neus ⁷, López-Vilariño, José A ⁵, Siguero, Mariano ⁵, Alfaro, Vicente ⁸, Zeaiter, Ali ⁵, Forster, Martin ⁹

Source: In International Journal of Gynecological Cancer November 2021 31(11):1428-1436

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Authors: Gaillard, Stephanie, Oaknin, Ana, Ray-Coquard, Isabelle, Vergote, Ignace, Scambia, Giovanni, Colombo, Nicoletta, Fernandez, Cristian, Alfaro, Vicente, Kahatt, Carmen, Nieto, Antonio, Zeaiter, Ali, Aracil, Miguel, Vidal, Laura, Pardo-Burdalo, Beatriz, Papai, Zsuzsanna, Kristeleit, Rebecca, O'Malley, David M., Benjamin, Ivor, Pautier, Patricia, Lorusso, Domenica

Source: In Gynecologic Oncology November 2021 163(2):237-245

Lurbinectedin in the treatment of relapsed small cell lung cancer

Authors: Baena, Javier, Modrego, Andrea, Zeaiter, Ali, Kahatt, Carmen, Alfaro, Vicente, Jimenez-Aguilar, Elizabeth, Mazarico, Jose María, Paz-Ares, Luis

Source: Future oncology. 17(18):2279-2289

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187740485.0x000001&indx=1&recIds=ETOCvdc_100187740485.0x000001

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Authors: Subbiah, Vivek ^*, Paz-Ares, Luis, Besse, Benjamin, Moreno, Victor, Peters, Solange, Sala, María Angeles, López-Vilariño, José Antonio, Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Zeaiter, Ali, Zaman, Khalil, López, Rafael, Ponce, Santiago, Boni, Valentina, Arrondeau, Jennifer, Delord, Jean-Pierre, Martínez, Maite, Wannesson, Luciano, Antón, Antonio, Valdivia, Javier, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Rubio, María Jesús, Sarantopoulos, John, Chawla, Sant P., Mosquera-Martinez, Joaquín, D’ Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M., Sands, Jacob, Trigo, José

Source: In Lung Cancer December 2020 150:90-96

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Authors: Trigo, José ^*, Subbiah, Vivek, Besse, Benjamin, Moreno, Victor, López, Rafael, Sala, María Angeles, Peters, Solange, Ponce, Santiago, Fernández, Cristian, Alfaro, Vicente, Gómez, Javier, Kahatt, Carmen, Zeaiter, Ali, Zaman, Khalil, Boni, Valentina, Arrondeau, Jennifer, Martínez, Maite, Delord, Jean-Pierre, Awada, Ahmad, Kristeleit, Rebecca, Olmedo, Maria Eugenia, Wannesson, Luciano, Valdivia, Javier, Rubio, María Jesús, Anton, Antonio, Sarantopoulos, John, Chawla, Sant P, Mosquera-Martinez, Joaquín, D'Arcangelo, Manolo, Santoro, Armando, Villalobos, Victor M, Sands, Jacob, Paz-Ares, Luis

Source: In The Lancet Oncology May 2020 21(5):645-654

Outstanding shortening of the activation process stage for a TiFe-based hydrogen storage alloy

Authors: Zeaiter, Ali, Nardin, Philippe, Pour Yazdi, Mohammad Arab, Billard, Alain

Source: In Materials Research Bulletin April 2019 112:132-141

Milling effect on the microstructural and hydrogenation properties of TiFe0.9Mn0.1 alloy

Authors: Zeaiter, Ali, Chapelle, David, Cuevas, Fermin, Maynadier, Anne, Latroche, Michel

Source: In Powder Technology November 2018 339:903-910

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

Authors: Ou, Sai-Hong Ignatius, Socinski, Mark A, Gadgeel, Shirish, Gandhi, Leena, West, Howard, Chiappori, Alberto Alejandro, Cohen, Victor, Riely, Gregory J, Smoljanovic, Vlatka, Bordogna, Walter, Wright, Elaine, Debusk, Kendra, Zeaiter, Ali, Shaw, Alice T

Source: In ESMO Open 2018 3(5)

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Authors: Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C., Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Zeaiter, Ali, Shaw, Alice T.

Source: In Journal of Thoracic Oncology October 2017 12(10):1552-1560

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria

Authors: Gandhi, Leena, Ou, Sai-Hong Ignatius, Shaw, Alice T., Barlesi, Fabrice, Dingemans, Anne-Marie C., Kim, Dong-Wan, Camidge, D. Ross, Hughes, Brett G.M., Yang, James C.-H., de Castro, Javier, Crino, Lucio, Léna, Hervé, Do, Pascal, Golding, Sophie, Bordogna, Walter, Zeaiter, Ali, Kotb, Ahmed, Gadgeel, Shirish

Source: In European Journal of Cancer September 2017 82:27-33

Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study.

Authors: Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Martínez, Sara, Iglesias, Jorge Luis, Calafati, Román Octavio, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin

Source: Marine Drugs; Apr2024, Vol. 22 Issue 4, p178, 15p

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Authors: Nishio, Makoto, Nakagawa, Kazuhiko, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Tanaka, Tomohiro, Kuriki, Hiroshi, Zeaiter, Ali, Tamura, Tomohide

Source: Lung cancer. 121:37-40

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100059368793.0x000001&indx=1&recIds=ETOCvdc_100059368793.0x000001

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Authors: Shaw, Alice T, Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J, Cetnar, Jeremy, West, Howard, Camidge, D Ross, Socinski, Mark A, Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H, Borghaei, Hossein, Gold, Kathryn A, Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ou, Sai-Hong Ignatius

Source: In The Lancet Oncology February 2016 17(2):234-242

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study.

Authors: Moreno, Irene, Hernández, Tatiana, Calvo, Emiliano, Fudio, Salvador, Kahatt, Carmen, Fernández, Cristian, Iglesias, Jorge Luis, Corral, Gema, Pérez-Ramos, Laura, Montilla, Lola, Zeaiter, Ali, Lubomirov, Rubin

Source: Pharmaceuticals (14248247); Feb2024, Vol. 17 Issue 2, p182, 15p

Subject Terms: DRUG interactions, PATIENT safety, CYTOCHROME P-450 CYP3A, PHARMACOKINETICS, DRUG labeling, TUMORS

Searching out the hydrogen absorption/desorption limiting reaction factors: Strategies allowing to increase kinetics

Authors: Zeaiter, Ali, Chapelle, David, Nardin, Philippe

Source: In Journal of Alloys and Compounds 5 October 2015 645 Supplement 1:S267-S270